Description

Product Description

Donafenib is a chemically synthesized small-molecule multikinase inhibitor designed as a next-generation derivative of sorafenib. Its chemical architecture incorporates fluorine substitutions and optimized linker regions, improving metabolic stability, bioavailability, and kinase selectivity. These properties make Donafenib an ideal research compound for in vitro, in vivo, and mechanistic oncology studies.

In cellular assays, Donafenib effectively inhibits RAF kinases (CRAF, BRAF) and receptor tyrosine kinases (VEGFR2, PDGFRβ), modulating MAPK/ERK pathways involved in tumor proliferation and angiogenesis. By binding to the ATP-binding pocket of these kinases, Donafenib prevents phosphorylation events required for downstream signal transduction, leading to reduced tumor cell proliferation, apoptosis induction, and impaired endothelial cell-mediated angiogenesis.

Preclinical studies employ Donafenib to investigate combination therapy potential, drug resistance mechanisms, and structure-activity relationships (SAR). Its dual inhibition of tumor and vascular signaling allows detailed studies of crosstalk between oncogenic pathways and microenvironmental responses. Researchers also use Donafenib in xenograft tumor models to evaluate tumor growth suppression, angiogenesis inhibition, and pharmacodynamic effects under controlled experimental conditions.

Donafenib is highly soluble in DMSO and ethanol and is supplied at ≥99% purity, ensuring reproducibility in experimental assays. Its chemical stability allows for high-fidelity research applications, including high-throughput kinase profiling, signaling pathway mapping, and in vitro mechanistic studies of cellular proliferation, apoptosis, and angiogenesis.

This compound is strictly for laboratory research and is not intended for clinical or veterinary use. Its reliable inhibitory profile and well-characterized pharmacology make Donafenib a cornerstone molecule for oncology, medicinal chemistry, and signal transduction research.

Product Specifications

Mechanism of Action

Donafenib inhibits both serine/threonine kinases (CRAF, BRAF) and receptor tyrosine kinases (VEGFR2, PDGFRβ), interfering with intracellular signaling that governs tumor cell proliferation and angiogenesis. By blocking ATP binding at the kinase active sites, Donafenib prevents phosphorylation and activation of downstream effectors such as MEK and ERK, leading to reduced cell cycle progression, increased apoptosis, and suppressed tumor growth.

The inhibition of VEGFR2 in endothelial cells impedes angiogenesis, reducing endothelial proliferation, migration, and tube formation in vitro and microvessel density in xenograft models. This dual targeting allows researchers to study interactions between tumor cells and the vascular microenvironment.

Donafenib is frequently used in combination studies to explore synergistic effects with chemotherapeutic agents, apoptosis modulators, or pathway-specific inhibitors. It also serves as a model compound for investigating compensatory signaling mechanisms, including PI3K/AKT/mTOR activation, in response to kinase inhibition.

Side Effects

In experimental systems, Donafenib exhibits dose-dependent cytotoxicity, cell cycle arrest, apoptosis induction, and oxidative stress modulation. These effects are mechanistic observations used to evaluate efficacy and pathway inhibition in research studies.

• Cell cycle arrest: Typically at G1 phase in sensitive tumor lines.

• Apoptosis: Activation of caspase-dependent and mitochondrial pathways.

• Oxidative stress: Elevated ROS contributes to apoptosis in preclinical models.

• Gene expression modulation: Changes in transcription factors like c-Myc, cyclin D1, VEGF-A.

• Endothelial effects: Reduced proliferation, migration, and tube formation.

These side effects are laboratory findings and not clinical adverse events. Proper lab safety practices must be observed, including PPE, fume hood usage, and controlled handling.

Keywords

Donafenib, CAS 1130115-44-4, multi-kinase inhibitor, RAF kinase inhibitor, VEGFR blocker, small molecule inhibitor, cancer research compound, oncology tool compound, angiogenesis pathway inhibitor, MAPK signaling modulator, high-purity kinase inhibitor, research chemical supplier, China peptide & chemical manufacturer, bulk small molecule inhibitor, lab-grade compound ≥99%.

Shipping Guarantee

All Donafenib shipments are handled using validated cold-chain logistics to preserve compound integrity. Each package is sealed in moisture-proof containers with secondary protective wrapping and continuous temperature monitoring. Products are shipped via express international couriers with full tracking and insurance coverage.

Trade Assurance

We Donafenib ensure product authenticity, verified ≥99% purity, and compliance with analytical standards (HPLC, MS, and NMR). Each batch is supplied with a Certificate of Analysis (CoA). Our trade assurance policy guarantees replacement or refund for any deviation from listed specifications.

Payment Support

We Donafenib provide flexible and secure global payment options to support international research transactions. Accepted payment methods include PayPal, major credit cards (Visa, MasterCard, American Express), telegraphic transfer (T/T), and cryptocurrencies (USDT, Bitcoin, Ethereum). All transactions are protected by industry-standard encryption and verified payment gateways to ensure confidentiality and fund security.

Disclaimer

All Donafenib products listed are intended for laboratory research use only and not for human or veterinary use. They are not drugs, medical devices, or diagnostics and should not be administered to humans or animals. Researchers must handle all materials in accordance with institutional biosafety and chemical safety guidelines. The information provided is for scientific reference only and does not imply therapeutic efficacy, safety, or regulatory approval.